Literature DB >> 16873763

Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome.

Evangelia I Prodromidi1, Richard Poulsom, Rosemary Jeffery, Candice A Roufosse, Patrick J Pollard, Charles D Pusey, H Terence Cook.   

Abstract

In a model of autosomally recessive Alport syndrome, mice that lack the alpha3 chain of collagen IV (Col4alpha3(-/-)) develop progressive glomerular damage leading to renal failure. The proposed mechanism is that podocytes fail to synthesize normal glomerular basement membrane, so the collagen IV network is unstable and easily degraded. We used this model to study whether bone marrow (BM) transplantation can rectify this podocyte defect by correcting the deficiency in Col4alpha3. Female C57BL/6 Col4alpha3(-/-) (-/-) mice were transplanted with whole BM from male wild-type (+/+) mice. Control female -/- mice received BM from male -/- littermates. Serum urea and creatinine levels were significantly lower in recipients of +/+ BM compared with those of -/- BM 20 weeks post-transplant. Glomerular scarring and interstitial fibrosis were also significantly decreased. Donor-derived cells were detected by in situ hybridization (ISH) for the Y chromosome, and fluorescence and confocal microscopy indicated that some showed an apparent podocyte phenotype in mice transplanted with +/+ BM. Glomeruli of these mice showed small foci of staining for alpha3(IV) protein by immunofluorescence. alpha3(IV) mRNA was detectable by reverse transcription-polymerase chain reaction and ISH in some mice transplanted with +/+ BM but not -/- BM. However, a single injection of mesenchymal stem cells from +/+ mice to irradiated -/- recipients did not improve renal disease. Our data show that improved renal function in Col4alpha3(-/-) mice results from BM transplantation from wild-type donors, and the mechanism by which this occurs may in part involve generation of podocytes without the gene defect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873763     DOI: 10.1634/stemcells.2006-0201

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  64 in total

Review 1.  Hematopoietic stem cell origin of mesenchymal cells: opportunity for novel therapeutic approaches.

Authors:  Makio Ogawa; Amanda C Larue; Patricia M Watson; Dennis K Watson
Journal:  Int J Hematol       Date:  2010-03-26       Impact factor: 2.490

2.  Injection of amniotic fluid stem cells delays progression of renal fibrosis.

Authors:  Sargis Sedrakyan; Stefano Da Sacco; Anna Milanesi; Liron Shiri; Astgik Petrosyan; Radka Varimezova; David Warburton; Kevin V Lemley; Roger E De Filippo; Laura Perin
Journal:  J Am Soc Nephrol       Date:  2012-02-02       Impact factor: 10.121

3.  Bone marrow-derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats.

Authors:  Catherine Meyer-Schwesinger; Claudia Lange; Verena Bröcker; Putri Andina Agustian; Putri Andina Agustian; Ulrich Lehmann; Annette Raabe; Martina Brinkmeyer; Eiji Kobayashi; Mario Schiffer; Guntram Büsche; Hans H Kreipe; Friedrich Thaiss; Jan U Becker
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

4.  Cellular origins of type IV collagen networks in developing glomeruli.

Authors:  Dale R Abrahamson; Billy G Hudson; Larysa Stroganova; Dorin-Bogdan Borza; Patricia L St John
Journal:  J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 10.121

5.  Stem cell therapy for Alport syndrome: the hope beyond the hype.

Authors:  Oliver Gross; Dorin-Bogdan Borza; Hans-Joachim Anders; Christoph Licht; Manfred Weber; Stephan Segerer; Roser Torra; Marie-Claire Gubler; Laurence Heidet; Scott Harvey; Dominic Cosgrove; George Lees; Clifford Kashtan; Martin Gregory; Judy Savige; Jie Ding; Paul Thorner; Dale R Abrahamson; Corinne Antignac; Karl Tryggvason; Billy Hudson; Jeffrey H Miner
Journal:  Nephrol Dial Transplant       Date:  2008-12-25       Impact factor: 5.992

6.  Adoptive transfer of syngeneic bone marrow-derived cells in mice with obesity-induced diabetes: selenoorganic antioxidant ebselen restores stem cell competence.

Authors:  Jun Chen; Houwei Li; Francesco Addabbo; Fung Zhang; Edward Pelger; Daniel Patschan; Hyeong-Cheon Park; Mei-Chuan Kuo; Jei Ni; Glenda Gobe; Praveen N Chander; Alberto Nasjletti; Michael S Goligorsky
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

7.  Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury.

Authors:  Florian Tögel; Arthur Cohen; Ping Zhang; Ying Yang; Zhuma Hu; Christof Westenfelder
Journal:  Stem Cells Dev       Date:  2009-04       Impact factor: 3.272

Review 8.  Hematopoietic stem cells are pluripotent and not just "hematopoietic".

Authors:  Makio Ogawa; Amanda C LaRue; Meenal Mehrotra
Journal:  Blood Cells Mol Dis       Date:  2013-02-27       Impact factor: 3.039

Review 9.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

10.  Stem cell therapies benefit Alport syndrome.

Authors:  Valerie LeBleu; Hikaru Sugimoto; Thomas M Mundel; Behzad Gerami-Naini; Elizabeth Finan; Caroline A Miller; Vincent H Gattone; Lingge Lu; Charles F Shield; Judah Folkman; Raghu Kalluri
Journal:  J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.